These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 3909336)

  • 1. Summary of worldwide clinical trials of aztreonam in patients with urinary tract infections.
    Swabb EA; Jenkins SA; Muir JG
    Rev Infect Dis; 1985; 7 Suppl 4():S772-7. PubMed ID: 3909336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of worldwide clinical trials of aztreonam in patients with lower respiratory tract infections.
    Swabb EA; Cone CO; Muir JG
    Rev Infect Dis; 1985; 7 Suppl 4():S675-8. PubMed ID: 3909323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aztreonam therapy for complicated urinary tract infections caused by multidrug-resistant bacteria.
    Cox CE
    Rev Infect Dis; 1985; 7 Suppl 4():S767-71. PubMed ID: 3909335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with aztreonam in four Mediterranean countries.
    Daikos GK
    Rev Infect Dis; 1985; 7 Suppl 4():S831-5. PubMed ID: 2934787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aztreonam in the treatment of urinary tract infection.
    Childs SJ
    Am J Med; 1985 Feb; 78(2A):44-6. PubMed ID: 3881948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aztreonam therapy for serious gram-negative infections in children.
    Stutman HR; Chartrand SA; Tolentino T; Friedhoff L; Marks MI
    Am J Dis Child; 1986 Nov; 140(11):1147-51. PubMed ID: 3766490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter comparative study of aztreonam and gentamicin in the treatment of renal and urinary tract infections.
    Albertazzi A; Bonadio M; Fusaroli M; Lotti T; Miano L; Salvia G; Sasdelli M; Villa G; Zucchelli P; Ventriglia L
    Chemotherapy; 1989; 35 Suppl 1():77-80. PubMed ID: 2659293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of low-dose aztreonam in the treatment of moderate to severe infections due to gram-negative bacilli.
    Clergeot A; Steru D; Rosset MA; Carbon C
    Rev Infect Dis; 1991; 13 Suppl 7():S648-51. PubMed ID: 2068476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of aztreonam in the treatment of patients with renal failure.
    Sion ML; Pyrpasopoulos M; Nicolaidis P; Papagianni C; Tsurutsoglu G
    Rev Infect Dis; 1991; 13 Suppl 7():S652-4. PubMed ID: 2068477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Brogden RN; Heel RC
    Drugs; 1986 Feb; 31(2):96-130. PubMed ID: 3512234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of aztreonam and cefamandole in the treatment of serious urinary tract infections.
    Tsouroutsoglou W; Sion ML; Stathopoulos GA; Kapoulas S; El-Messidi M; Paradelis AG
    Methods Find Exp Clin Pharmacol; 1983; 5(6):385-90. PubMed ID: 6684719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with aztreonam.
    Stutman HR
    Pediatr Infect Dis J; 1989 Sep; 8(9 Suppl):S109-12; discussion S128-32. PubMed ID: 2682508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with aztreonam in Germany and Austria.
    Stille W; Gillissen J
    Rev Infect Dis; 1985; 7 Suppl 4():S825-30. PubMed ID: 3909342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aztreonam in the treatment of urinary tract infections: a multicenter trial.
    Martelli A; Cortecchia V; Ventriglia L
    Chemotherapy; 1989; 35 Suppl 1():8-14. PubMed ID: 2659294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Aztreonam vs norfloxacin: a comparative study of the treatment of urinary tract infections in ambulatory and hospitalized patients].
    Puppo P; Germinale F; De Rose AF
    Clin Ter; 1989 Apr; 129(2):113-21. PubMed ID: 2525996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical use of aztreonam.
    Schönwald S; Schoss-Vidensek Z; Car V; Krznar B
    Chemotherapy; 1989; 35 Suppl 1():45-8. PubMed ID: 2731450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aztreonam: worldwide overview of the treatment of patients with gram-negative infections.
    Henry SA; Bendush CB
    Am J Med; 1985 Feb; 78(2A):57-64. PubMed ID: 3881950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
    Scully BE; Neu HC
    Am J Med; 1985 Feb; 78(2):251-61. PubMed ID: 4038574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aztreonam: early clinical studies in New Jersey.
    Johnson ES; Eng RK; Perez EM; Smith LG
    N J Med; 1986 Jan; Spec No():26-9. PubMed ID: 3513061
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of aztreonam and tobramycin in the treatment of lower respiratory tract infections caused by gram-negative bacilli.
    Nolen TM; Phillips HL; Hall HJ
    Rev Infect Dis; 1985; 7 Suppl 4():S666-8. PubMed ID: 3909321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.